Compare Stocks → A lot of people are making this costly mistake (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AZRXNASDAQ:EYEGNASDAQ:FBRXNASDAQ:INNTNASDAQ:OHRP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAZRXAzurRx BioPharma$3.95-0.5%$4.04$3.36▼$26.30$36.84M1.51628,703 shs42,349 shsEYEGAB Corporate Bond ETF$35.75+0.1%$1.90$1.44▼$8.18$451.12M0.81935,975 shsN/AFBRXForte Biosciences$0.70$0.68$0.38▼$1.29$25.29M0.4827,901 shs52,347 shsINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shs253 shsOHRPOHR Pharmaceutical$0.45+4.7%$7.37$1.60▼$6.28$1.27M0.84180,228 shs282,210 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAZRXAzurRx BioPharma0.00%-11.83%-33.50%-5.95%+45.76%EYEGAB Corporate Bond ETF+0.06%+0.60%+1.50%-0.69%+1,733.31%FBRXForte Biosciences+0.19%+0.90%+1.61%-15.27%-28.84%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.92%OHRPOHR Pharmaceutical0.00%-57.80%-52.89%-38.86%+149.83%The ProTrader Dashboard is simple to use! (trade demo inside) (Ad)Top traders like Kathy, Philip, Matt and Michael made out like bandits… “Took 65% profit on VFC today! Thanks!” - Kathy L. “Made 72% on VFC” - Philip “VFC was good, made $1,000 bucks” - Matt (estimated starting stake $1K) “VFC crushed it… Up 114% for a $3,249 profit!” - Michael It’s all thanks to the all-new ProTrader Dashboard… And today’s your chance to become one of the lucky ones to discover it for yourself.Click here to discover this institutional-grade trading tool for yourself. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAZRXAzurRx BioPharmaN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AFBRXForte Biosciences2.00HoldN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAZRXAzurRx BioPharmaN/AN/AN/AN/A($0.76) per shareN/AEYEGAB Corporate Bond ETF$10K45,112.29N/AN/A$1.26 per share28.37FBRXForte BiosciencesN/AN/AN/AN/A$0.97 per shareN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/AOHRPOHR PharmaceuticalN/AN/AN/AN/A$3.86 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAZRXAzurRx BioPharma-$32.67M-$11.50N/AN/AN/AN/A-482.96%-258.47%N/AEYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/AFBRXForte Biosciences-$31.48M-$1.04N/A∞N/AN/A-94.27%-81.36%5/20/2024 (Estimated)INNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/AOHRPOHR Pharmaceutical-$13.23MN/A0.00∞N/AN/A-75.46%-71.18%N/ALatest EYEG, FBRX, OHRP, AZRX, and INNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023FBRXForte BiosciencesN/A-$0.04-$0.04-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAZRXAzurRx BioPharmaN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AFBRXForte BiosciencesN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AOHRPOHR PharmaceuticalN/AN/AN/AN/AN/ALatest EYEG, FBRX, OHRP, AZRX, and INNT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/20241/31/2024EYEGAB Corporate Bond ETFMonthly$0.14762/1/20242/2/20242/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAZRXAzurRx BioPharmaN/A1.331.33EYEGAB Corporate Bond ETF0.013.073.07FBRXForte BiosciencesN/A10.4510.45INNTInnovate BiopharmaceuticalsN/A0.350.35OHRPOHR PharmaceuticalN/A3.733.73OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAZRXAzurRx BioPharma6.27%EYEGAB Corporate Bond ETF64.16%FBRXForte Biosciences77.63%INNTInnovate Biopharmaceuticals5.88%OHRPOHR Pharmaceutical10.70%Insider OwnershipCompanyInsider OwnershipAZRXAzurRx BioPharma7.30%EYEGAB Corporate Bond ETF58.20%FBRXForte Biosciences10.53%INNTInnovate Biopharmaceuticals7.90%OHRPOHR Pharmaceutical12.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAZRXAzurRx BioPharma129.33 million8.65 millionNot OptionableEYEGAB Corporate Bond ETF1412.62 million5.28 millionNot OptionableFBRXForte Biosciences936.40 million32.56 millionOptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableOHRPOHR Pharmaceutical32.83 millionN/ANot OptionableEYEG, FBRX, OHRP, AZRX, and INNT HeadlinesSourceHeadlineCYCC Cyclacel Pharmaceuticals, Inc.seekingalpha.com - March 17 at 4:20 PMSun Pharmaceutical Industries Ltd.moneycontrol.com - February 3 at 8:52 AMAI Advances Pharmaceutical Packaging Inspectiondesignnews.com - May 22 at 9:22 AMThe OHRP and SUPPORT — Another Viewnejm.org - April 21 at 3:16 PMWorking at the Smithsoniansi.edu - February 23 at 5:49 PMOHR Pharmaceutical (OHRP) is now in Oversold Territoryca.finance.yahoo.com - September 12 at 11:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAzurRx BioPharmaNASDAQ:AZRXAzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.AB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.Forte BiosciencesNASDAQ:FBRXForte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.OHR PharmaceuticalNASDAQ:OHRPOHR Pharmaceutical, Inc. operates as a development stage pharmaceutical company. The company intends to merge with NeuBase Therapeutics, Inc. that focuses on advancing NeuBase's peptide-nucleic acid antisense oligonucleotide technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. OHR Pharmaceutical, Inc. is headquartered in New York, New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.